









Markets
/
Stocks
/
nasdaq-rnxt
/

RenovoRx Inc

RNXT

View Detailed Chart

1.210USD

-0.030-2.42%

Close 08/01, 16:00（ET）Quotes delayed by 15 min

44.22MMarket Cap

LossP/E TTM



RenovoRx Inc

1.210

-0.030-2.42%

Overview Company Financials

Financials

Intraday

30m

Today

-2.42%

5 Days

-4.72%

1 Month

-11.03%

6 Months

-11.68%

Year to Date

-6.20%

1 Year

-1.63%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 4 analysts

BUY

Current Rating

5.500

Target Price

354.55%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

117

Total

Median

Average

Company name

Ratings

Analysts

RenovoRx Inc

RNXT

Medtronic PLC

MDT

Stryker Corp

SYK

Abbott Laboratories

ABT

Zimmer Biomet Holdings Inc

ZBH

Dexcom Inc

DXCM

...

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Sell

Sell(7)

Neutral(2)

Buy(2)

Indicators

Sell(3)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.022

Sell

RSI(14)

40.990

Neutral

STOCH(KDJ)(9,3,3)

15.066

Oversold

ATR(14)

0.055

Low Volatility

CCI(14)

-125.323

Sell

Williams %R

94.737

Oversold

TRIX(12,20)

-0.288

Sell

StochRSI(14)

46.436

Neutral

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

1.224

Sell

MA10

1.253

Sell

MA20

1.286

Sell

MA50

1.317

Sell

MA100

1.152

Buy

MA200

1.169

Buy

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

RenovoRx, Inc. is a clinical-stage biopharmaceutical company. The Company is developing targeted combination therapies for high unmet medical needs with a goal of improving therapeutic outcomes for cancer patients undergoing treatment. Its Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. Its portfolio of cancer therapies is based on its lead product candidate, RenovoGem (gemcitabine delivered via its delivery system). Its phase III lead product candidate, RenovoGem, is a novel oncology drug-device combination product. RenovoGem is being evaluated for the treatment of locally advanced pancreatic cancer (LAPC) by the Center for Drug Evaluation and Research. Its phase III registrational trial of RenovoGem for the treatment of LAPC is called TIGeR-PaC.

Ticker SymbolRNXT

CompanyRenovoRx Inc

CEOMr. Shaun R. Bagai

Websitehttps://renovorx.com/